Offer document regarding the offer to the shareholders of AdderaCare made public
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Offer document regarding the offer to the shareholders of AdderaCare made public

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA OR THE UNITED STATES (THE ”RESTRICTED JURISDICTIONS”), OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED "IMPORTANT INFORMATION" AT THE END OF THIS ANNOUNCEMENT AND IN THE OFFER DOCUMENT.

On 17 November 2022, MedCap AB (publ) (”MedCap”) announced a recommended public offer to the shareholders of AdderaCare AB (publ) (”AdderaCare”) to tender all shares in AdderaCare at a price of SEK 3.60 in cash per share (the ”Offer”). The Offer is implemented through Abilia Sverige Holding AB, reg. no. 556682-1251, a subsidiary of MedCap.

The offer document is available on MedCap’s website (www.medcap.se) and on Aktieinvest’s website (www.aktieinvest.se/emission/adderacare2022). A pre-printed acceptance form and a pre-paid envelope will be distributed to shareholders in AdderaCare whose shares are directly registered with Euroclear Sweden AB on 2 December 2022, subject to applicable offer restrictions.

The acceptance period for the Offer commences on 2 December 2022 and ends on 23 December 2022 (the acceptance period might be extended). Settlement is expected to commence on or around 2 January 2023, provided that the conditions for the Offer have been fulfilled or MedCap has otherwise decided to complete the Offer.
 

Information regarding the Offer

Information about the Offer is available at: www.medcap.se

Anders Dahlberg, CEO, MedCap

Tel: +46 704 269 262, e-mail: [email protected]

For administrative questions regarding the Offer, please contact primarily your bank or nominee where you have your shares registered.

About MedCap

MedCap builds successful life sciences companies to improve people's lives. MedCap unites the strengths of a larger company with the smaller companies' entrepreneurial power, agility, and business acumen. MedCap is publicly listed on NASDAQ Stockholm OMX, with the symbol MCAP. More information is available on the company web site www.medcap.se.


The information in this press release has been published by MedCap, through the agency of the contact person, in accordance with the Takeover Rules. This press release was submitted for publication on 1 December 2022, at 8.30 (CET).

Bifogade filer

Nyheter om MedCap

Läses av andra just nu

Om aktien MedCap

Senaste nytt